Patrys Adds Full Human Antibody to Deoxymab Portfolio
(WorldNews Japan)

ASX & Media Release Full human antibody added to Patrys` pre-clinical Deoxymab portfolio Patrys has successfully completed the initial production and characterisation of PAT-DX3, a full- sized, humanised version of its Deoxymab antibody fragment PAT-DX1 PAT-DX3has demonstrated functional equivalence with PAT-DX1 in several important attributes including the ability to penetrate the cell nucleus, and the ability to bind to the DNA that is released from damaged tumour cells Differences between the underlying pharmacologies of PAT-DX1 and PAT-DX3 may expand options for developing novel cancer therapies PAT-DX3is protected by existing granted and pending patents in key jurisdictions...